Indication intelligence, analysis and sector perception

Cytori Therapeutics (CYTX) enhances its reagent clinical platform - BUY

December 1, 2015 10:21am

Signs a non-exclusive, 3 year distribution agreement with Worthington Biochemical Corporation for the Celase GMP enzyme

Celase® GMP is a proprietary enzyme containing a unique blend of collagenase, neutral protease and buffer salts that are produced using avian and mammalian tissue-free raw materials, aseptically processed, sterile filtered and highly purified under cGMP guidelines. Integrating Celase® GMP into cell isolation study protocols can facilitate a smooth transition from bench and animal research to downstream clinical applications.

The Bottom Line: Agreement potentially broadens the number of clinical applications for Cytori Cell Therapy. The analogy could be developing ab app utilizing CYTX’s source code to facilitate <translational> research. Key is a revenue source – everything and anything helps.

CYTX closed at $0.36 with 2 M share traded and is down -$0.01 to $0.36 on 136.9 K shares trading <3 month average = 1.369 M shares>. It's so cheap - BUY

35 companies, 1 interpreter!

Insight, foresight and recommendation

What's Happening Today

1 hour 39 min ago
RegMed Investors (RMi) Closing Bell: I told you so

10 hours 27 min ago
RegMed Investors’ (RMi) pre-open: It’s “make” a buck day!

My motto … never leave an investor uninformed! I say today what others won’t, so you can do what others can’t.

My name is Henry McCusker; I endorse these opinions under my own name and with a subscription based membership.

Do you have an opinion you would like to share with us? We would like to hear from you.

Please e-mail us at hwm@regmedinvestors.com.

Editor and Publisher ... Henry McCusker enters his tenth (10th) year at RegMed Investors with past experience in sell-side analysis, buy-side management, corporate management and due diligence.

RegMed Investors (RMi) or Regmedinvestors.com content is the intellectual property of Henry McCusker. Any copying, republication or redistribution of RMI’s content, including by framing or similar means, is expressly prohibited without the prior written consent of Scimitar; who also shall not be liable for any errors or delays in content, or for any actions taken in reliance thereon. For additional information on other Scimitar media services or reposting please email hwm@regmedinvestors.com.

The information included above as well as individual companies and/or securities mentioned should be construed as guidance in RMi reviews.

The facts stated and the opinions given in this publication are based on data and information considered to be reliable and have been carefully worked into my qualitative analyses and prognoses. However, no guarantee can be given as to their fairness, accuracy or completeness.

Henry McCusker, the editor and publisher of RegMed Investors does not hold or have positions in securities referred to in this publication.